COLL Stock Overview
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 2/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Collegium Pharmaceutical, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$37.51 |
| 52 Week High | US$40.95 |
| 52 Week Low | US$20.83 |
| Beta | 1.05 |
| 1 Month Change | -4.92% |
| 3 Month Change | 14.22% |
| 1 Year Change | 63.73% |
| 3 Year Change | 63.09% |
| 5 Year Change | 165.65% |
| Change since IPO | 205.21% |
Recent News & Updates
Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24
Recent updates
Collegium Pharmaceutical Q4: The Beat Goes On
Feb 26These 4 Measures Indicate That Collegium Pharmaceutical (NASDAQ:COLL) Is Using Debt Reasonably Well
Feb 24There's No Escaping Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Muted Revenues
Jan 05Here's Why Collegium Pharmaceutical (NASDAQ:COLL) Can Manage Its Debt Responsibly
Nov 12Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Aug 09Is Collegium Pharmaceutical (NASDAQ:COLL) A Risky Investment?
Mar 10Is Collegium Pharmaceutical (NASDAQ:COLL) Using Too Much Debt?
Oct 18Collegium Pharmaceutical (NASDAQ:COLL) Has A Somewhat Strained Balance Sheet
Jun 24Collegium Pharmaceutical: Oversold And Cheap
Jun 12Collegium Pharmaceutical: Thoughts After Another Strategic Move
Feb 20There Is A Reason Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) Price Is Undemanding
Feb 15We Think Collegium Pharmaceutical (NASDAQ:COLL) Can Stay On Top Of Its Debt
Oct 30Sizing Up Collegium Pharmaceuticals
Oct 04Collegium Pharmaceutical: Moving Closer To The Top
Jul 12Collegium Pharmaceutical, Inc.'s (NASDAQ:COLL) CEO Compensation Is Looking A Bit Stretched At The Moment
May 14Shareholders Will Be Pleased With The Quality of Collegium Pharmaceutical's (NASDAQ:COLL) Earnings
May 13Shareholder Returns
| COLL | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 3.0% | 1.1% | 0.7% |
| 1Y | 63.7% | 9.5% | 23.9% |
Return vs Industry: COLL exceeded the US Pharmaceuticals industry which returned 12% over the past year.
Return vs Market: COLL exceeded the US Market which returned 24.2% over the past year.
Price Volatility
| COLL volatility | |
|---|---|
| COLL Average Weekly Movement | 5.2% |
| Pharmaceuticals Industry Average Movement | 10.0% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in US Market | 16.7% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: COLL has not had significant price volatility in the past 3 months.
Volatility Over Time: COLL's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 197 | Joe Ciaffoni | www.collegiumpharma.com |
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain. The company was formerly known as Collegium Pharmaceuticals, Inc. and changed its name to Collegium Pharmaceutical, Inc. in October 2003.
Collegium Pharmaceutical, Inc. Fundamentals Summary
| COLL fundamental statistics | |
|---|---|
| Market cap | US$1.23b |
| Earnings (TTM) | US$48.16m |
| Revenue (TTM) | US$566.77m |
25.5x
P/E Ratio2.2x
P/S RatioIs COLL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| COLL income statement (TTM) | |
|---|---|
| Revenue | US$566.77m |
| Cost of Revenue | US$79.72m |
| Gross Profit | US$487.05m |
| Other Expenses | US$438.89m |
| Earnings | US$48.16m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 09, 2024
| Earnings per share (EPS) | 1.47 |
| Gross Margin | 85.93% |
| Net Profit Margin | 8.50% |
| Debt/Equity Ratio | 341.4% |
How did COLL perform over the long term?
See historical performance and comparison